CBLL1 and non-small cell lung carcinoma: A decrease in E-cadherin and increase in Hakai levels were observed in clinical samples of non-small cell lung cancer with acquired resistance to gefitinib and knockdown of Hakai-elevated E-cadherin expression and attenuated stemness of cancer cells, which resensitised the cells to gefitinib [44].